Loading
A phase 2 trial of SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06465563 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 93 participants enrolled, started 2024-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Gemcitabine, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/